Acceso abierto

The prevalence of ER-low-positive breast cancer and its relation to tumor characteristics in Syria

Remal Abdulaziz Asaad

Remal Abdulaziz Asaad

Clinical Biochemistry, Department of Biochemistry and Microbiology, Faculty of Pharmacy, Tishreen UniversityLatakia, Syria
Buscar este autor en
Sciendo|Google Scholar
Asaad, Remal Abdulaziz
, 
Hla Sudan

Hla Sudan

Master in Laboratory Diagnosis, Department of Biochemistry and Microbiology, Faculty of Pharmacy, Tishreen UniversityLatakia, Syria
Buscar este autor en
Sciendo|Google Scholar
Sudan, Hla
, 
Bailasan Hasan

Bailasan Hasan

Master in Laboratory Diagnosis, Department of Biochemistry and Microbiology, Faculty of Pharmacy, Tishreen UniversityLatakia, Syria
Buscar este autor en
Sciendo|Google Scholar
Hasan, Bailasan
 y 
Siraj Saadaldin Abdullah

Siraj Saadaldin Abdullah

Department of Surgery, National Hospital of JablehLatakia, Syria
Buscar este autor en
Sciendo|Google Scholar
Abdullah, Siraj Saadaldin
  
28 sept 2024
The prevalence of ER-low-positive breast cancer and its relation to tumor characteristics in Syria's Cover Image
Acerca de este artículo
Artículo anterior
Artículo siguiente
Cite
Descargar portada
Categoría del artículo: Research Article
Publicado en línea: 28 sept 2024
Páginas: 56 - 62
Recibido: 20 ene 2024
Aceptado: 21 may 2024
DOI: https://doi.org/10.2478/fco-2023-0028
Palabras clave
© 2024 Remal Abdulaziz Asaad et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Figure 1:

Mean of CRP levels according to ER status in BC patients.
Mean of CRP levels according to ER status in BC patients.

Figure 2:

ROC curve of CRP levels for predicting high ER+. Cutoff value of CRP was 4.7mg/l with specificity 52%, sensitivity 80%, and AUC 0.68 (P<0.05).
ROC curve of CRP levels for predicting high ER+. Cutoff value of CRP was 4.7mg/l with specificity 52%, sensitivity 80%, and AUC 0.68 (P<0.05).

Comparison between ER-low-positive and ER-high-positive BC_

ER-staining intensity subtypes
Parameter Low N=28 (23.33%) High N=30 (25%) P value
n % n %
Age, years ≤46 14 50 4 13.33 0.003
>46 14 50 26 86.67
Tumor size, cm ≤2cm 10 35.71 6 23.33 0.189
2.1 to 5 12 42.86 20 61.67
>5 6 21.43 4 15
Diagnosis IDC 26 92.86 26 86.67 0.695
ILC 2 7.14 2 6.67
Mucinous 0 0 2 6.67
Histological grade I 0 0 0 0 0.05
II 16 57.14 28 93.33
III 6 42.86 2 6.67
Stage I 0 0 2 6.67 0.009
II 6 21.43 16 53.33
III 22 78.57 12 40
Nodal stage, pN 1 to 4 2 7.14 14 46.67 0.001
>4 26 92.86 16 53.33
LNR Low risk (0–0.2) 2 7.14 16 53.33 0.001
Intermediate risk (>0.2–0.65) 22 78.57 12 40
High risk (>0.65–1) 4 14.29 2 6.67

General characteristics of tumor and study population_

Classification n %
Diagnosis IDC 108 90
ILC 8 6.67
Mucinous 4 3.33
Age (years) ≤46 56 46.6
>46 64 53.3
Tumor size (cm) T1: ≤2cm 28 23.33
T2: 2.1 to 5 74 61.67
T3: >5 18 15
Histologic grade I 2 1.67
II 100 83.33
III 18 15
Stage I 6 5
IIA 18 15
IIB 38 31.67
IIIA 48 40
IIIB 10 8.33

Characteristics of patients and tumor according to ER status_

ER-staining intensity subtypes N=120
Parameter Negative N=38 (31.67%) Low N=28 (23.33%) Moderate N=24 (20%) High N=30 (25%) P value
n % n % n % n %
Age, years ≤46 22 57.89 14 50 16 66.67 4 13.33 0.018
>46 16 42.11 14 50 8 33.33 26 86.67
Tumor Size, cm ≤2cm 2 5.26 10 35.71 10 41.67 6 23.33 0.18
2.1 to 5 30 78.95 12 42.86 12 50 20 61.67
>5 6 15.79 6 21.43 2 8.33 4 15
Diagnosis IDC 34 89.47 26 92.86 22 91.67 26 86.67 0.812
ILC 4 10.53 2 7.14 0 0 2 6.67
Mucinous 0 0 0 0 2 8.33 2 6.67
Histological grade I 0 0 0 0 2 8.33 0 0 0.01
II 34 89.47 16 57.14 22 91.67 28 93.33
III 4 10.53 6 42.86 0 0 2 6.67
Stage I 2 5.26 0 0 2 8.33 2 6.67 0.131
II 24 63.16 6 21.43 10 41.67 16 53.33
III 12 31.58 22 78.57 12 50 12 40
Nodal stage, pN 1 to 4 20 52.63 2 7.14 10 41.67 14 46.67 0.035
>4 18 47.37 26 92.86 14 58.33 16 53.33
LNR Low risk (0–0.2) 20 52.63 2 7.14 10 41.67 16 53.33 0.046
Intermediate risk (>0.2–0.65) 18 47.37 22 78.57 18 50 12 40
High risk (>0.65–1) 0 0 4 14.29 2 8.33 2 6.67
Idioma:
Inglés
Calendario de la edición:
2 veces al año
Temas de la revista:
Medicina, Medicina Clínica, Medicina Interna, Hematología, oncología
RSS Feed de revista